KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Other Non-Current Liabilities (2018 - 2025)

Historic Other Non-Current Liabilities for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $1.5 million.

  • Castle Biosciences' Other Non-Current Liabilities changed N/A to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year change of. This contributed to the annual value of $25000.0 for FY2023, which is 7222.22% down from last year.
  • Latest data reveals that Castle Biosciences reported Other Non-Current Liabilities of $1.5 million as of Q3 2025.
  • Castle Biosciences' 5-year Other Non-Current Liabilities high stood at $18.3 million for Q4 2021, and its period low was $16000.0 during Q1 2024.
  • In the last 5 years, Castle Biosciences' Other Non-Current Liabilities had a median value of $95000.0 in 2022 and averaged $2.1 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first surged by 168235.87% in 2021, then crashed by 9950.78% in 2022.
  • Quarter analysis of 5 years shows Castle Biosciences' Other Non-Current Liabilities stood at $18.3 million in 2021, then crashed by 99.51% to $90000.0 in 2022, then plummeted by 72.22% to $25000.0 in 2023, then tumbled by 36.0% to $16000.0 in 2024, then surged by 9275.0% to $1.5 million in 2025.
  • Its Other Non-Current Liabilities stands at $1.5 million for Q3 2025, versus $1.5 million for Q2 2025 and $16000.0 for Q1 2024.